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University of Pittsburgh, 2009 
 
HIV infects and depletes CD4+ T cells in Gut Associated Lymphoid Tissues 
(GALT) of the Gastrointestinal (GI) tract at a very early stage of infection. 
Furthermore, GALT are the major reservoirs of HIV-1 and may constantly shed 
virus and CD4+ T cells into the intestinal lumen throughout the entire course of 
infection. We hypothesize that the dynamic changes of HIV-1 and CD4+ T cell 
quantities in feces are linked to disease progression and can be used to predict 
disease prognosis. The aims of this study are to establish sensitive methods for 
detection and quantitation of HIV-1 and CD4 mRNA in feces, and to use the 
methods to monitor the amount of HIV-1 RNA/DNA and CD4 mRNA in feces 
samples of HIV infected patients and to correlate the findings with disease 
progression. In addition, since urine may potentially serve as a vehicle for HIV-1 
transmission we have also measured HIV-1 RNA/DNA in the urine samples from 
the same population used for the feces study. Our results showed that using normal 
feces spiked with known copies of DNA and RNA, as low as 2.5 copies of HIV-1 
DNA and 40 copies of HIV-1 RNA were detected per input in both nested PCR 
and RT-nested PCR reactions respectively. Human CD4 mRNA was also detected 
in feces. From HIV-1 infected volunteers of the Multicenter AIDS Cohort Study 
(MACS), HIV-1 DNA, RNA and human CD4 mRNA was detected in 8%, 19% 
and 31%, respectively, in the feces samples from patients with detectable viral load 
in blood.  In the urine samples from the same study population, HIV-1 DNA was 
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detected in 26% of HIV-1 infected donors and this detection is not always 
correlated with the presence of detectable viral load in blood. This study has major 
Public health significance as it demonstrates that HIV-1 RNA/DNA could be 
detected in feces and urine samples, which may lead to the development of a future 
non-invasive approach to evaluate disease progression and prognosis. In addition, 
our study demonstrated, for the first time, the presence of human CD4 mRNA in 
fecal specimens of infected donors, which could be used as a valuable tool in the 
future to assess the pathogenesis of Gut Associated Lymphoid Tissue over the 
course of HIV-1 infection.  
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1.0 INTRODUCTION 
 
1.1 HIV-1 infection: 
Human immunodeficiency virus-1 (HIV-1) is a lentivirus, which can lead to 
Acquired Immunodeficiency Syndrome (AIDS), a condition in humans in which 
the immune system begins to fail, leading to life-threatening opportunistic 
infections.  
  
1.1.1 Epidemiology of HIV-1 infection:  
UNAIDS and WHO estimate in 2007 that AIDS has killed more than 25 million 
people since it was first recognized in 1981, making it one of the most destructive 
pandemics in recorded history. Despite recent improved access to antiretroviral 
treatment and care, in 2007 alone, AIDS killed an estimated 2.1 million people 
including 330,000 children and there were 2.5 million new infections with total 
33.2 million people living with HIV[1, 2]. Sub-Saharan Africa remains by far the 
worst-affected region, with more than 22.5 million of total infected people. South 
and South East Asia are second-worst affected with 4.0 million infected people. 
 
Figure 1: The Global Summary of the HIV/ AIDS Epidemics 
Source: www.unaids.org 
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1.1.2 Transmission of HIV-1:  
The majority of HIV-1 infections are acquired through unprotected sexual contact. 
Sexual transmission can occur through the genital, rectal or oral mucous 
membranes with the risk of female-to-male transmission of 0.04% per act and 
male-to-female transmission of 0.08% per act. For various reasons, these rates are 
4 to 10 times higher in developing countries[3]. HIV-1 is also transmitted through 
contacting HIV-1 infected blood and/or blood products. This transmission route 
can account for infections in intravenous drug users, hemophiliacs, recipients of 
blood transfusion and health-care workers. HIV-1 could also be transmitted from 
infected mother to the child during pregnancy (through placenta), child birth 
(exposure to mother blood) and breast feeding[4]. HIV-1 has been found at low 
concentrations in the saliva, feces, tears and urine of infected individuals, but the 
potential risk of HIV-1 transmission through these vehicles is currently considered 
low[2, 5] . 
1.1.3 HIV-1 replication cycle:  
The primary target cells for HIV are human CD4 positive T cells. HIV enters 
CD4+ T cells or other target cells through interaction of HIV-1 envelope proteins 
gp120 with human CD4 (HIV receptor) and CCR5/CXCR4 (HIV-1 co- receptors) 
on the cell surface and release viral capsid into the cells. Once the viral capsid 
enters the cell, viral reverse transcriptase (RT) transcribes the single positive 
stranded viral RNA genome into a complementary DNA followed by formation of 
double stranded viral DNA intermediate which is integrated into the host genome 
by viral integrase. Progeny virions are produced from the infected cells through 
transcription of HIV-1 genes from integrated viral DNA, leading to production of 
HIV proteins and full-length copies of the HIV-1 RNA genome. To produce 
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mature viral particles, viral envelope glycoprotein gp160 is cleaved by viral 
protease into glycoproteins gp120 and gp41 and then transported to the plasma 
membrane of the host cell. The Gag-pol polyprotein gets associated at the inner 
surface of the plasma membrane with HIV-1 genomic RNA and undergoes a 
maturation process where HIV-1 protease cleaves the polyproteins into individual 
functional HIV proteins and enzymes. These various structural components then 
assemble to produce mature HIV virions by budding out of the infected cells 
(Figure 2) [6]. 
 
Figure 2: HIV-1 Life Cycle  
Source: Coffin, J., 1995. Science 267:483-489 
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1.1.4 The clinical course of HIV-1 infection: 
Natural infection of HIV-1 infection has four stages: incubation period, acute 
infection, latency stage and AIDS (figure3). The initial incubation period is 
asymptomatic and usually lasts between two and four weeks following HIV 
infection. The second stage, acute infection, lasts an average of 30 days. During 
this period patients generally show symptoms such as fever, swollen lymph nodes, 
rash, mouth and esophageal sores and malaise. In the latency stage, patients show 
few or no clinical symptoms and this stage can last anywhere from two weeks to 
twenty years and beyond. In AIDS, the fourth and final stage of HIV-1 infection, 
patients show symptoms of various opportunistic infections, weight loss, & 
diarrhea. 
An acute HIV infection is associated with a burst of HIV-1 viremia and an abrupt 
decline of CD4+ T cells in the peripheral blood due to HIV-1 cytotoxicity and 
immune destruction. Within a few weeks of primary infection, HIV-1 viremia 
decreases and CD4+ T cell counts rebound due to anti-HIV specific immune 
response in the body. At this stage, patients are often unaware of the HIV-1 
infection since it causes only mild flu-like symptoms in clinic.  However, in the 
acute stage of infection, HIV disseminates extensively and establishes multiple 
viral reservoirs in the body, which sets up clinically latent phase of infection.  
During the clinical latency, the CD4+T cell counts continue to decrease. When 
CD4+ T cell counts fall below a critical level, the infected person becomes 
susceptible to opportunistic infections and AIDS develops [7].  
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Figure 3: Clinical courses of HIV-1 infection  
Source: Fauci, A. S., Ann. Intern. Med., 124:654,1996 
1.1.5 Current methods for diagnosis of HIV-1 infection: 
Blood is the most commonly used specimen for testing and diagnosis of HIV-1 
infection. The primary tests for diagnosing HIV and AIDS include: 
Serologiocal assay Test: Enzyme-linked immunosorbent assay (ELISA), is used 
to detect anti-HIV antibodies. If an ELISA test is positive, the Western blot test is 
performed to confirm the diagnosis. ELISA is quite sensitive for testing chronic 
HIV infection. However, because antibodies aren't produced immediately upon 
infection, the test may be negative during a period of a few weeks to a few months 
after being infected.  
Viral Load Test: This test measures the amount of HIV-1 RNA genome in blood 
and is used to detect early HIV infection or to monitor therapeutic efficacy. The 
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three most commonly used technologies for measuring HIV viral load in the blood 
are reverse transcription polymerase chain reaction (RT-PCR), branched DNA 
(bDNA) and nucleic acid sequence-based amplification assay (NASBA). The basic 
principles of these tests are similar: HIV is detected by amplification of viral DNA 
or RNA.  
CD4+T Cell Count: CD4+T cells are depleted at very early stage of HIV-1 
infection. The CD4+T cell count in a blood sample is commonly measured by a 
flowcytometry based method and used to assess the disease progression. The 
CD4+ T cell count correlates with a person's risk of developing opportunistic 
infections and is a useful marker for HIV disease staging and treatment planning. 
The Center for Disease Control and Prevention (CDC) recommends CD4+T testing 
every three to six months in all HIV-1infected patients, although the need may 
vary from individual to individual. 
1.2 Mucosal Associated Lymphoid Tissue and HIV-1 Infection: 
The mucosal immune system, including the lymphoid tissues in nasal, bronchial, 
gastrointestinal and urogenital systems, is an integral component of our body to 
protect us from microbial infections. The mucosal immune system provides the 
first line of defense against the invading pathogens through a cluster of uniquely 
organized lymphoid tissues known as Mucosa-associated lymphoid tissue (MALT) 
(Figure 4). Natural transmission of HIV-1 occurs through mucosal surfaces and 
thus HIV-1 is considered a mucosal pathogen. Mucosal transmission of Simian 
Immunodeficiency Virus(SIV) has been shown experimentally in non-human 
primates through oral, rectal and vaginal mucosa [8]. 
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Figure 4: Schematic representation of gut-associated lymphoid tissue (GALT), with organized 
lymphoid structures. 
Source: Honjo et al, Nature Reviews Immunology, 3, 63-72, Jan 2003 
 
1.2.1 The mucosa Associated Lymphoid Tissues: structure and functions  
The largest component of the mucosal immune system is the Gut Associated 
Lymphoid Tissue (GALT), which resides in the Gastrointestinal tract (GI tract) [9].  
GALT can be functionally divided into inductive and effector sites. The inductive 
sites include mesenteric lymph nodes, Peyer’s Patches (PP) and lymphoid follicles, 
where the antigen specific immune responses are initiated. The effector sites 
include lamina propria (LP) and the epithelium, where the antigen specific immune 
responses are implemented. The surface of PP are covered by a unique epithelial 
layer known as the follicle-associated epithelium (FAE) which contains specialized 
antigen-sampling cells-microfold cells(M cells). M cells can deliver intact antigens 
from intestinal lumen to antigen presenting cells (APCs) residing in the basal 
membrane side of the M cells[10] . Following acquiring and processing of the 
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antigens, APCs migrate to the B cell (germinal centers) and T-cell zones in the PP 
to present the antigens to T and B cells. After the recognition and activation of 
immune cells, the antigen specific T cells and B cells emigrate from the inductive 
sites via lymphatic drainage, circulate through the bloodstream and reach the 
effector sites of GALT. The effector sites, mainly LP regions, contain 
predominantly memory T cells, natural killer cells and B cells (Figure 5)[11, 12]. 
When the immune cells are re-exposed to the specific antigen, strong cellular and 
humoral immune responses occur in the effector sites.   
 
 
Figure 5: Depiction of the human mucosal immune system 
Source: Russell M, Nature Reviews immunology, 2008, 2,31 
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1.2.2 Dysfunction of Mucosal immune system during acute HIV-1 and SIV 
infections: 
HIV-1 and SIV target the lower gastrointestinal tract as an initial site of infection 
showed by the  studies performed on human and Simian models [13]. The lamina 
propria in rectal mucosa contains an abundant amount of lymphoid cells, especially 
CD4+ memory T cells expressing CCR5, the most commonly infected cells 
following HIV-1 infection. In experimental SIV infection of macaque models, the 
early accumulation of SIV-infected lymphocytes and high viral load in GI mucosa 
were observed compared to blood and lymph nodes, which indicated that the GI 
mucosa is the initial and predominant site of SIV infection [13]. A series of studies 
have revealed the early immunologic events of HIV-1 and SIV infection at the 
mucosal tissue level[14]. These studies concluded that early HIV-1/SIV infection 
is consistently associated with a dramatic and largely irreversible depletion of 
mucosal CD4+memory T cells, particularly those expressing HIV-1/SIV 
coreceptor CCR5[15]. In contrast, CD4+ T cells residing in the peripheral blood 
and lymph nodes are relatively preserved. The possible explanation for depletion 
of CD4+ T cells from the GI tract may involve several factors: 1) a direct infection 
accounting for the earliest loss and 2) activation induced death mediated by host 
cytotoxic cellular responses. Similar studies with human models to evaluate the 
events occurring in the mucosal system following HIV-1 infection are extremely 
difficult to perform for ethical reasons. Though few groups conducted these kind of 
studies, and their data clearly indicate that HIV-1 infection also leads to an early, 
rapid depletion of mucosal CD4+CCR5 memory T cells[16]. Thus based on these 
studies it can be concluded that a selective depletion of memory CD4+ T cells 
from mucosal tissues during acute HIV or SIV infection is a key determinant of the 
disease progression. This early loss of CD4+ T cells from mucosal tissues leads to 
an impairment of mucosal immunity that may lead to the downstream chronic 
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infection. It should also be noted that the exact hypothesis for the viral 
pathogenicity for this early depletion of CD4+ T cells in gut is still unclear and 
needs further investigation. 
 
1.2.3 Dysfunction of Mucosal immune system during chronic HIV-1 and SIV 
infection: 
In the chronic phase of infection the immune system exerts some control over a 
steady state viral replication. However, the overall state of chronic and general 
immune activation plays a central role for a progressively dysfunctional immune 
system [17].During chronic HIV infection the extent of GALT CD4+ T cell 
depletion remains more severe, mainly involving CD4+ CCR5 + T cells residing in 
the lamina propria as observed in tissue specimens collected from the terminal 
ileum[18].A subsequent study on SIV mac239-infected rhesus macaques revealed 
that after the acute depletion of CD4+T cells, a consistent and progressive decline 
in the CD4+ T cells is observed during  chronic infection which coincides with a 
similarly progressive exhaustion of CD4+ central memory T cells at the level of 
blood and lymph node[19]. In addition, this study showed a progressive, systemic 
decline of CD4+ central memory T cells that resulted in insufficient mucosal 
CD4+ effector memory T cells that are associated with the progression of AIDS. 
This systemic loss of CD4+ central memory T-cells during chronic SIVmac239 
infection of macaques was more closely associated with the immune activation 
than viral load, thus consistent with the chronic immune activation in HIV-1 
infection[9]. In HIV-1 infected individuals low levels of mucosal CD4+ T cell and 
increased mucosal immune response are associated with increased collagen 
deposition in the lymph nodes, thus suggesting a parallel loss of effector memory 
and central memory T-cell function in mucosal and systemic lymphoid tissues 
respectively during chronic progressive HIV-1 disease [20].The target cell 
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distribution and HIV-1 replication in the intestinal tract has been shown below in 
Figure 6. 
 
Figure 6: Target cell distribution and HIV-1 replication in the intestinal tract 
Source: Leckner et al, J. Exp.Med, 200, 697, 2004 
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1.3 Detection of HIV-1 in feces sample: 
Since HIV infects GALT in the early phase of infection and GALT serves as a 
viral reservoir throughout the entire course of infection, a patient’s feces may 
provide a convenient specimen for monitoring HIV-1 related pathogenesis.   
 
1.3.1 Human feces: composition and prevalence of viral communities: 
Human feces also known as stool are the waste product of the human digestive 
system and it varies significantly in appearance, composition and pathology 
depending upon the state of human health and diet. About 3/4 portion of normal 
feces is made of water.  The remaining portion is a mixture of dead bacteria, fats 
such as cholesterol, inorganic salts like phosphates, live bacteria, dead cells and 
mucus from the lining of the intestine, and proteins [21]. Clinically, fecal samples 
have been used for laboratory tests of micropathogens or parasites for diagnosis 
and monitoring disease progression. Three main types of laboratory tests are 
commonly performed with fecal samples to detect pathogens, Enzyme linked 
ImmunoSorbent assay (ELISA), microscopic examination for intestinal parasites 
and routine culture to find bacterial pathogens.  
 
The human gastrointestinal tract is known to be a natural habitat for a large 
microbial community including bacteria, archaea, eukarya and viral pathogens. 
Many viral pathogens have been detected from the feces of gastroenteritis patients 
including astrovirus, rotavirus, coronavirus, calcivirus and adenovirus[12, 22]. A 
comparative metagenomic analysis of the RNA viruses in fecal samples revealed 
that plant viruses are prevalent in the normal human feces. Further study revealed 
that the most common animal virus identified in human feces was a 
picornavirus(PBV-733)[23].The other viruses identified in human feces in 
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abnormal gastrointestinal conditional are the Hepatitis-C virus[24] and the Human 
immnuodeficiency Virus-1(HIV-1) and other enteric RNA viruses.[25]. 
 
1.3.2 Detection of Human Immunodeficiency Virus Type-1 from Feces 
samples: 
HIV-1 infects and depletes CD4+ T cells in GALT of GI tract at very early stages 
of infection and the HIV associated GALT pathogenesis is maintained throughout 
the entire course of infection[26]. Detection of HIV-1 has been reported[25] in 
fecal specimens from HIV-1 infected individuals in acute phase of infection and 
without any therapeutic intervention. Although no HIV-1 proviral DNA was 
detected in feces, HIV-1 RNA was detected in 67% of patients’ fecal samples by 
RT-PCR. Direct sequencing revealed differences in sequence heterogeneity of the 
PCR amplimers obtained from paired fecal and serum specimens. The HIV-1 RNA 
detected in feces could be either from infected cells or free virus shed from the 
lamina propria, which pass through the epithelial barrier because of the increased 
permeability of the epithelial cell layer [27].It is not clear whether the HIV-1 
contained in feces could pose a threat to the public health. However one report 
showed that a full-length SIVcpz sequence (TAN1) was isolated from the feces of 
an infected chimpanzee from Gombe National Park (Tanzania)[28-30].  
 
1.4     Detection of HIV in Urine Sample: 
 
1.4.1: Structure and function of urinary system: 
The urinary system is the organ system that produces, stores, and eliminates urine. 
In humans it includes two kidneys, two ureters, the bladder, and the urethra as 
shown below in Figure 7. The urinary system keeps chemicals, such as potassium 
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and sodium, and water in balance, urea and other excretory product from the body. 
Glomerulus is a very important structure of the urinary/excretory system which 
performs the role of the basic filtration system of the kidney. The resistance of the  
glomerular- arterioles results in high pressure in the glomerulus aiding the process 
of ultrafiltration where fluids and soluble materials in the blood are forced out of 
the capillaries and into Bowman's capsule[31]. The structures of the glomerulus 
determine their permeability-selectivity, called as permselectivity. The factors that 
influence permselectivity are the negative charge of the basement membrane and 
the podocytic epithelium, and the effective pore size of the glomerular wall (8 nm). 
As a result, large and/or negatively charged molecules pass through far less 
frequently than small and/or positively charged ones. For instance, small ions such 
as sodium and potassium pass freely, while larger proteins, such as hemoglobin 
and albumin have practically no permeability at all[32, 33]. 
Now in abnormal conditions such as during viral infection, inflammation occurs in 
glomerular walls and the permeability changes due to disruption of the selective 
pressure that keeps the larger particles like protein, virus and cells going through 
the glomerulus. We hypothesize that the glomerular walls undergoes inflammation 
and causes disruption of the selective pressure during HIV-1 infection. As a result 
it creates a possibility that HIV-1 RNA/DNA could shed from urinary tract to urine 
through the glomerulus. Pathogenic changes in uro-genital system are very 
common in HIV-1 infected patients. Monitoring urine samples may provide 
important information for HIV infection and its related disease progression.    
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Figure 7: Structural organization of Human urinary system 
Source: www.bioedonline.com 
 
1.4.2 Human Urine: composition and prevalence of invading pathogens: 
The urine is composed of mainly water, dissolved salts and organic compounds. 
Urine is generally colorless and sterile. However, in pathogenic conditions, 
micropathogens can be detected in urine. The most commonly identified bacterial 
pathogens in urine are salmonella typhi, salmonella paratyphi, Leptospira, Yersinia 
and E.coli[34]. In patients with acute viral infections, the virus is commonly 
present in the blood, occasionally in the cerebrospinal fluid and the urine. 
Detection of cytomegalovirus, human papillomavirus in human urine has been 
reported previously[35, 36] 
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1.4.3 Detection of Human Immunodeficiency Virus Type-1 from Urine 
samples: 
HIV-1 has been isolated from various body fluids from HIV-1 seropositive 
individuals, including blood, semen, tears, saliva, cerebrospinal fluid, breast milk 
and cervical secretions[37, 38]. With the increasing prevalence of HIV-1 infection, 
assessment of HIV-1 contained in urine from infected individuals can be extremely 
important since urine could serve as a vehicle for HIV-1 transmission. It has been 
reported that anti-HIV-1 antibodies were detected in urine by ELISA and Western 
blot [39]and that  HIV-1 DNA were detected in urine pellets from HIV-1-infected 
individuals[27]. Moreover, HIV-1 p24 core antigen and HIV-1 RNA were detected 
in the cells contained in urine from HIV-1-seropositive individuals by 
immunohistochemical staining and in situ hybridization [33, 40]. A broad spectrum 
of renal diseases has been described in HIV infected patients with symptomatic 
HIV-1 disease [40].  Studies in a nephropathy revealed that rapidly advancing renal 
insufficiency, nephritic disorders and glomerular sclerosis occur in HIV-1 infected 
patients[41]. It is highly possible that monitoring HIV-1 amount in urine and 
correlating the detected HIV-1 quantities with the disease progression may become 
extremely significant for future diagnosis and preventive approaches. 
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2.0 STATEMENT OF THE PROBLEM AND AIMS OF STUDY 
 
HIV-1 replication results in massive tissue damage and CD4+ T cell depletion in 
GALT.  In the entire course of HIV infection, the HIV-1 constantly sheds from 
GALT into the intestinal lumen in the form of free virus and/or cell associated 
virus particles. In addition, increased numbers of infected and uninfected CD4+ T 
cells are also shed from GALT into the intestinal lumen. So far no comprehensive 
studies have been performed to correlate the detection of HIV RNA/DNA and CD4 
mRNA in feces and urine with disease progression, which is important for possible 
future development of a non-invasive clinical diagnostic method and therapeutic 
interventions. Urinary complications are common in HIV-1 infected patients with 
several clinical manifestations, but whether it can serve as a vehicle for HIV-1 
transmission is poorly understood. We hypothesize that the HIV-1RNA/DNA and 
CD4+ T cell quantities identified in feces and urine are linked to disease 
progression and can be used to predict disease prognosis. To address these 
questions three specific aims will be emphasized in this study.  
 
SPECIFIC AIMS: 
 
• SPECIFIC AIM #1: Standardization of sensitive methods for the detection 
of HIV-1 DNA/RNA and CD4 mRNA in human feces. 
 
• SPECIFIC AIM #2: Detection of HIV-1 DNA/RNA and human CD4 
mRNA in fecal specimens of the Multicenter AIDS Cohort Study volunteers 
and correlation of the findings with disease stages.  
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• SPECIFIC AIM #3: Detection of HIV-1 DNA/RNA in urine specimens of 
Multicenter AIDS Cohort Study volunteers and correlation of the outcome 
with results from the blood and fecal specimens.  
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3.0 MATERIALS AND METHODS 
 
3.1 Study Participants:  
The normal and HIV-1 infected population used in this study is part of the 
Multicenter AIDS Cohort Study in Pittsburgh. The Multicenter AIDS Cohort Study 
(MACS) is an ongoing prospective study of the natural and treated histories of 
HIV-1 infection in homosexual and bisexual men conducted by sites located in 
Baltimore, Chicago, Pittsburgh and Los Angeles. The MACS was designed to 
elucidate the natural history of the infection causing acquired immunodeficiency 
syndrome (AIDS), identify risk factors for occurrence and clinical history of the 
infection, and establish a repository of biologic specimens for future study.  The 
study participants for our project are from the Pittsburgh site of MACS who signed 
the consent forms and completed a survey questionnaire following all Institutional 
Review Board (IRB) guidelines before donating the biologic specimens. The 
participation in this research study was completely voluntary and the donors had 
the right to withdraw from participation at any time.  Fecal specimens were 
collected from 11 consented HIV-1 seropositive MACS donors in year 2007. Later 
in the year 2008, biologic specimens were collected from the subjects in four 
different groups: Group A: HIV-1 negative; Group B: HIV-1 positive but not on 
Highly Active Antiretroviral Therapy (HAART); Group C: HIV-1 positive on 
HAART with non-detectable viral load; Group D: HIV-1 positive on HAART with 
detectable viral load (Table 3).      
 
3.2 Collection and storage of biological specimens:  
All participants were contacted before the visit to our clinic with instructions to 
collect stool samples at home within 24 hours before their visit to the clinic. They 
were provided with special stool collection tube (SARSTEDT) and urine collection 
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cups (Falcon) to store the samples. Within six hours after the samples arrived in 
clinic, feces samples were stored in RNAlater solution (AMBION) or Cell-Lysis 
buffer in -80C freezer. Urine samples were collected at the clinic and stored in 4C 
temporarily and processed within 6 hours after collection. In addition, all the study 
participants also donated blood samples at the same time of feces and urines 
collection. Plasma, serum and PBMC were isolated from these blood samples and 
used for CD4 count and viral load measurement.  
 
3.3 HIV-1 infected cell line:  
The 8E5 cell line, derived from HIV-1-infected CD4+ CEM cells, carries a single, 
integrated and RT-defective HIV-1 genome. The lack of functional RT production 
by this genome is the consequence of a frame-shift mutation in the pol gene, due to 
a single base addition at position 3241. These CD4+ T cells express gag and env 
proteins and produce HIV particles which are non-infectious[42]. 
  
3.4 HIV-1 positive plasma and virus culture:   
The HIV-1 positive plasma with known copy number used for spiking normal 
feces before nucleic acid isolation was obtained from a HIV-1 infected Brazilian 
blood donor (subtype B) with plasma. Viral load in plasma for this sample was 
170,000copies/ml.  Virus culture supernatant containing 270ng/ml p24 of a 
Chinese subtype B’ HIV-1 isolate was used for spiking normal donor feces for the 
HIV-1 p24 measurement by ELISA.  
 
3.5 Extraction of RNA/DNA from feces samples:  
200mg of feces sample were used to isolate RNA/DNA using nucleic acid isolation 
kit from BIOMERIEUX [25]. Fecal specimens stored in Cell- Lysis buffer after 
collection at -80C were thawed and mixed completely by vortexing or inverting. 
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50ul of silica bead suspension was immediately added to the sample and the 
sample mixture was incubated at room temperature for 10 min. with vortexing 
every 2 min. to allow the nucleic acids to bind to the beads. Then, the sample was 
vortexed again and centrifuged for 3 min. at 1500g to pellet the silica. The 
supernatant was carefully removed to avoid disturbing the silica pellet and the 
pellet was washed five times: 2 times with wash buffer, 2 times with 70% ACS 
grade ethanol and 1 time with analytical grade acetone. The silica-nucleic acid 
complexes were dried on a heat block at 56C for 10 min. and nucleic acids were 
eluted using 100ul of elution buffer. Eluted nucleic acids were immediately stored 
at -70C for further use. Under these conditions, the nucleic acids are stable and can 
be used for a wide variety of applications.  
 
3.6 Extraction of RNA/DNA from urine samples: 
26-83ml of urine samples were collected from consented MACS donors and 
processed within a 6 hour time frame. These urine samples were centrifuged at 
3000rpm for 10 min. at 4C. The urine pellets were saved in -80C for DNA 
isolation. The urine supernatant was concentrated by a Centricon plus-70 filter 
with molecular weight cutoff 100kDa (Amicon centricon plus-70, Ultracel PL-100, 
MWCO: 100kDa, Millipore) according to manufacture’s instruction. Briefly, urine 
supernatant was centrifuged in a pre-wet Centricon at 500g for 1.5hrs and the 
concentrated supernatant was collected by inverted spinning and further 
concentrated by ultracentrifugation at 22,000rpm for one hour at 4C. Finally 50ul 
of concentrated supernatant was saved at -80C for further RNA isolation.   
 
         RNA was purified from the concentrated urine supernatant using RNA-Bee 
RNA Isolation kit (TEL-TEST, INC) according to manufacture’s instruction. 
Briefly, 1ml of RNA-Bee solution and 200ul of chloroform were added to the 
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concentrated urine supernatant and shaken vigorously for 30 seconds at room 
temperature. Then, the sample was incubated in 4C for 5 minutes and centrifuged 
at 12,000g for 15 minutes at 4C. After centrifugation, the aqueous phase containing 
RNA was carefully recovered. The RNA was precipitated using isopropanol, 
washed with 75% Ethanol, air dried and stored in nuclease free water at -80C for 
future RT-PCR work. 
 
               DNA was purified from the urine pellet using PUREGENE DNA 
Purification Kit (GENTRA SYSTEMS) according to manufacture’s instruction. 
Briefly, urine pellet was resuspended in 900ul of Cell Lysis Solution and incubated 
at 65C for 30 min. After incubation, 5ul of RNase A Solution was added to the 
mixture and incubated at 37C for 30min. Then, 300ul of Protein Precipitation 
Solution was added to the mixture, which was vortexed and centrifuged at 2000g 
for 10 minutes. DNA was precipitated from the supernatant by isopropanol, 
washed by 70% ethanol and air dried. The DNA was re-hydrated in nuclease free 
water and stored at -20C for subsequent PCR work. 
             
3.7 Nested PCR and RT-PCR:  
Nested PCR and RT-PCR were performed on isolated RNA/DNA samples from 
Feces and Urine to quantitate HIV-1 and CD4 mRNA. Specific primers listed in 
Table 1 were used for optimal detection of HIV-1 subtype B env and gag regions, 
human beta-globin DNA, human beta-actin mRNA and CD4 mRNA.     
 
First a cDNA strand was generated using Superscript II RT (Invitrogen, Carlsbad, 
CA). A 10ul reaction consisting of 10ug of RNA, 2uM of primer, 10mM dNTP 
mix, and H2O was incubated at 70°C for 10 minutes. Following incubation, 5x RT 
buffer, 0.1 M DTT, RNA guard (RNase) (40U/ul), and Superscript II RT (200U/ul) 
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was added respectively. The reaction was incubated in H20 bath at 42°C for 50 
minutes followed by a second incubation in dry bath at 70C for 10 minutes. 
Amplification of specific target sequences in the cDNA was performed using 10μl 
cDNA, forward and reverse primer pairs, dNTPs, Taq polymerase buffer and Taq-
polymerase enzyme in Thermocycler (Applied Biosystems) with cycling 
conditions of 94º C, 10 min followed by 35 cycles of 94º C, 1min, 55º C, 1min, 72º 
C, 1 min. Presence of the amplicon was analyzed on a 1%-2.5% agarose gel in 1X 
TAE buffer. The primers used for PCR/RT-PCR and Nested PCR/RT-PCR 
amplification are listed in Table 1. 
 
Table 1: The primers used for PCR/RT-PCR and Nested PCR/RT-PCR 
amplification 
Name  Sequences (5’       3’) Description 
ED31 CCT CAG CCA TTA CAC AGG CCT GTC CAA AG 1st round PCR forward primer for 
HIV env gp120 
BH2 CCT TGG TGG GTG CTA CTC CTA ATG GTT CA 1st round PCR reverse primer for 
HIV env gp120 
DR7 TCA ACT CAA CTG CTG TTA AAT GGC AGT CTA 
GC 
2nd round PCR forward primer 
for HIV env gp120 
DR8 CAC TTC TCC AAT TGT CCC TCA TAT CTC CTC 
C 
2nd round PCR reverse primer 
for HIV env gp120 
Hu-CD4 
Inside F 
CTC CCG CTC CAC CTC ACC CTG 2nd round PCR forward primer 
for Human CD4 mRNA 
Hu-CD4 
Inside R 
CAT GTG GGC AGA ACC TTG ATG TTG G 2nd round PCR reverse primer for 
Human CD4 mRNA 
Hu-CD4 
outside  F 
CCA AGT CTT GGA TCA CCT TTG ACC TGA AG 1st round PCR forward primer for 
Human CD4 mRNA 
Hu-CD4 
outside  R 
AGA AGA AGA TGC CTA GCC CAA TGA AAA GC 1st round PCR reverse primer for 
Human CD4 mRNA 
B-globin 
inside F 
GGT TCT TTG AGT CCT TTG GGG ATC 2nd round PCR forward primer 
for Human Beta globin DNA 
B-globin GTC ACA GTG CAG CTC ACT CAG TGT G 2nd round PCR reverse primer for 
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inside R Human Beta globin DNA 
B-globin 
outside F 
CTG CTG GTG GTC TAC CCT TGG AC 1st round PCR primer for Human 
Beta globin DNA 
B-globin 
outside R 
CTC AAG TTC TCA GGA TCC A 1st round PCR primer for Human 
Beta globin DNA 
B-actin 
inside F 
TAC CAC TGG CAT CGT GAT GGA CTC 2nd round PCR primer for Human 
Beta actin RNA 
B-actin 
inside R 
CGC TCA TTG CCA ATG GTG ATG AC 2nd round PCR primer for Human 
Beta actin RNA 
B-actin 
outside F 
GCA CCA CAC CTT CTA CAA TG 1st round PCR primer for Human 
Beta actin RNA 
B-actin 
outside R 
TGC TTG CTG ATC CAC ATC TG 1st round PCR primer for Human 
Beta actin RNA 
Gag inside F GGC ACA TCA AGC AGC CAT GCA AAT G 2nd round PCR primer for HIV 
Gag 
Gag inside R TAG TTC CTG CTA TGT CAC TTC CCC TTG G 2nd round PCR primer for HIV 
Gag 
Gag outside 
F 
GGC CAT ATC ACC TAG AAC TTT AAA TGC ATG 
G 
1st  round PCR primer for HIV 
Gag 
Gag outside 
R 
CCT ACT GGG ATA GGT GGA TTA TTT GTC ATC 
CA 
1st round PCR primer for HIV 
Gag 
Hu-CD4 RT 
primer 
ATG TCT TCT GAA ACC GGT GAG GAC ACT G RT primer 
ED12 AGT GCT TCC TGC TGC TCC CAA GAA CCC AAG RT primer 
 
 
3.8 Measurement of HIV-1 p24 from feces sample by ELISA: 
Supernatant derived from feces sample was measured for p24 concentration by a 
commercial available HIV p24 ELISA kit (PerkinElmer Life Sciences, Inc., MA, 
USA).  
In order to standardize the HIV-1 p24 detection limit, normal donor feces sample 
were spiked with HIV-1 virus (Chinese isolate, subtype B’) in serial dilutions and 
then treated with protease inhibitors. These samples were then mixed completely 
(Table 1 continued) 
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by vortexing and incubated for 10min at room temperature. These inhibitors are 
capable of inhibiting a broad spectrum of serine, cysteine and metalloproteases as 
well as calpains and thus suitable for the protection of protein degradation.  
Subsequently, the samples were vortexed again and centrifuged for 3 min. at 
1500g. Supernatant was saved for measurement of HIV-1 p24 antigen by HIV-1 
p24 ELISA kit. 
  
200mg of fecal specimens from MACS participants were resuspended in 800ul of 
PBS containing the protease inhibitor cocktail (Roche Applied Science, Catalog 
No. 11836153001), mixed completely by vortexing and incubated for 10 min. at 
room temperature. These inhibitors are capable of inhibiting a broad spectrum of 
serine, cysteine and metalloproteases and are suitable for the protection of proteins 
[43].  Subsequently, the samples were vortexed again and centrifuged for 3 min. at 
1500g. Supernatant was saved for measurement of HIV-1 p24 antigen by HIV-1 
p24 ELISA kit. 
 
3.9 Detection of fecal occult blood from feces samples: 
Feces samples from MACS donors were tested for presence of occult blood by a 
Hemoccult II SENSA kit (BECKMAN COULTER, Catalog no. 395035). Trace 
amount of the fecal sample was smeared onto an absorbent paper that has been 
treated with a chemical guaiac. Hydrogen peroxide was dropped onto the fecal 
smear. If trace amounts of blood was present, blue color development would occur. 
A total of 39 fecal specimens from four different groups of 2008 MACS donors 
(Table 2) were tested. In addition, one normal donor fecal sample was included as 
negative control and normal donor fecal sample mixed with blood as positive 
control.  
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4.0 RESULTS 
 
SPECIFIC AIM #1: Establishment of sensitive methods for detection of HIV-
1 DNA/RNA and human CD4 mRNA in feces. 
 
4.1 Exploration of the most suitable technique for isolating nucleic acid from 
feces samples:  
Feces components are very complex and contain nucleases proteases, proteins and 
nucleic acids from human as well as animals, plants and microbes. Since quality 
and quantity of isolated nucleic acids from feces are the keys for successful PCR 
amplification, column based isolation (QIAGEN) and silica based isolation 
(NUCLISENS) and elution methods have been compared and we found that the 
NUCLISENS (BIOMERIEUX INC) method is the most effective one in terms of 
DNA/RNA quality and quantity, which has been used in all of our subsequent 
experiments. 
 
4.2 Evaluation of the sensitivity of the detection assay for HIV-1 DNA/RNA 
in human feces: 
 
4.2.1 The nested PCR sensitivity for detection of HIV-1 DNA:  
We have used nested PCR to detect HIV-1 DNA/RNA in feces. In order to test the 
sensitivity, 200mg of normal donor fecal sample was spiked with different 
concentrations of HIV-1 positive 8E5 cells. DNA was isolated using NUCLISENS 
(BIOMERIEUX) nucleic acid isolation kit. For every DNA sample, the human 
beta-globin gene was PCR amplified to ensure that the isolated DNA was 
amplifiable and contained the comparable amount of human DNA. Figure 8B 
shows the representative results of PCR amplification of beta globin DNA from 
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three feces samples. Subsequently, a nested PCR reaction was performed to detect 
HIV-1 DNA from the isolated DNA using HIV-1 env specific primers. (Figure 8A) 
which was visualized by electrophoresis in 1% agarose gel. As shown in Figure 
8C, HIV-1 DNA was detected from the DNA isolated from normal donor feces 
spiked with 8E5 cells. The detection limit was as low as 2.5 copies/ reaction. 
A. 
pNL4-3 env with primer locations
2565 bp
DR8DR7
ED31 BH2
ED12 RT Primer
V1 V2 V3 V4 V5
gp120
gp41
 
 
  
Figure 8A: Schematic representation of HIV-1 env primer. 
           8B. PCR was performed in isolated DNA using beta globin specific primers: lane 1 from 
normal stool, lane 2-3 from normal feces spiked with 25 and 2.5 8E5 cells respectively, lane 4 
PCR negative controls  
           8C.Nested PCR was performed in isolated DNA using HIV-1 env specific primers: lane 
1-3 from normal feces only, lane 4 from normal feces spiked with 2.5 
8E5 cells, 5-6 from 500 and 50 8E5 cells as positive control, lane 7 PCR negative controls.  
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4.2.2 The nested RT-PCR sensitivity for detection of HIV-1 RNA:   
Two hundred milligrams normal donor feces were spiked with different 
concentrations of HIV-1 positive plasma (with known HIV-1 RNA copies) and 
nucleic acid was isolated using NUCLISENS nucleic acid isolation kit. Initially, 
HIV-1 env specific RT primer, ED12, was used to synthesize cDNA from isolated 
RNA followed by nested-PCR reaction using the HIV-1 env specific primer that 
was used for HIV-1 DNA amplification. As the human RNA input control in each 
sample, cDNA was synthesized by random hexamer followed by nested PCR 
amplification using human beta-actin mRNA specific primers. As shown in Figure 
9, HIV-1 RNA was detected in isolated RNA from normal feces spiked with HIV-
1 positive plasma. To evaluate the influence of other non-human nucleic acid 
contained in the feces on the RNA isolation and PCR amplification procedures, 
RNA was isolated and amplified in parallel from the same HIV-1 positive plasma 
alone. A similar detection limit was observed with HIV-1 RNA as low as 
40copies/reaction in the plasma sample with or without the presence of feces. 
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Figure 9. Quantitation of HIV-1 RNA in normal donor feces spiked w/HIV positive Plasma: 
Nested RT-PCR was performed using HIV-1 env specific primers in RNA isolated from normal 
feces only (lane 5) or spiked with HIV-1 positive plasma containing 1000 (lane 1), 200 (lane 2), 
40 (lane 3) or 8 copies (lane 4) of HIV-1. The PCR run for same HIV-1 positive plasma as 
control (lane 6-10).   
 
4.3 Detection of Human CD4 mRNA from human feces: 
To monitor the evidence of human CD4+T cells shedding from GALT to feces, 
human CD4 mRNA specific RT and nested PCR primers were designed (Table 1) 
and used to detect CD4 mRNA from feces.  Two hundred milligrams normal donor 
feces sample were spiked with different concentrations of CD4+ 8E5 cells and then 
nucleic acids were isolated. Human CD4 specific cDNA was synthesized using 
CD4 RT primer followed by nested-PCR amplification with CD4 specific primer 
set ( Figure 10A). The final PCR product of 341bp was visualized in 2.5% agarose 
gel. Figure 10B, shows that CD4 mRNA was not detected from normal donor 
feces, but was detected in feces sample spiked with 50 8E5 cells. 
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A. 
B. 
NM 000616 human CD4-1
770 bp
CD4
Insider F inside R
out Rout F RT Primer
CD4
CD4
CD4 CD4
 
 
 
Figure  10A. Schematic representation of Human CD4mRNA Primer. 
           10B. Detection of Human CD4 mRNA from normal feces with or without 8E5 cells. 
Nested RT-PCR was performed in RNA from normal feces using human CD4 mRNA specific 
primers: lane 1—normal feces only, lane 2—normal feces spiked with 50 8E5 cells, lane 3---50 
8E5 cell only as positive control, and lane 4—PCR negative control. 
 
4.4   Detection of HIV-1 p24 antigen from fecal sample: 
To detect HIV-1 protein from human fecal specimen, HIV-1 p24 ELISA was 
performed since p24 antigen is the most abundant structural component of the 
virus. Two hundred milligrams of normal donor feces sample were spiked with the 
virus culture supernatant after a serial dilutions ranging from 1:45 to 1:295245 
(Chinese HIV-1 subtype B’ isolate). Then these fecal extracts were tested for HIV-
1 p24 antigen. To evaluate the influence of common fecal components, such as 
proteases (bacterial, microbial, plant) on the protein processing and detection, the 
same series of supernatant dilutions were also tested for HIV-1 p24. ELISA data in 
figure 11 shows that the detection limit is 15pg/ml and similar amount of HIV-1 
31 
 
p24 in the fecal extracts spiked with HIV-1 positive culture supernatant was also 
detected as compared to that of the same concentration of HIV-1 positive culture 
supernatant samples alone. 
 
 
Figure 11: HIV-1 p24 was detected from normal donor feces sample spiked with HIV-1 virus. 
HIV-1p24 was not detected from normal donor feces as negative control. 
 
SPECIFIC AIM #2: Detection of HIV-1 DNA/RNA and human CD4 mRNA in 
fecal specimens of the Multicenter AIDS Cohort Study volunteers and correlation 
of the findings with disease stages. 
 
4.5: Detection of HIV-1 RNA/DNA from 2007 MACS volunteers fecal 
specimens: 
 
4.5.1: Frozen fecal specimens from 2007 MACS Volunteers: 
A total of 10 fecal specimens were collected from MACS volunteers and frozen in 
RNA later solution in 2007. Among these 10 volunteers, five subjects were on 
antiretroviral therapy (HAART) without detectable viral load in blood. Five 
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subjects were without antiretroviral therapy (HAART) and with detectable viral 
load ranging from 14,690 to 58,768 (Table 2) 
 
Table 2: Clinical information of 2007 Multicenter AIDS Cohort Study (MACS) 
Volunteers.  
 
 
4.5.2: Detection of HIV-1 DNA/RNA from 2007 MACS Volunteer fecal 
specimens: 
Whole nucleic acid was isolated using NUCLISENS method from 200mg fecal 
sample followed by nested DNA PCR and nested RT -PCR using the same primer 
set described previously. HIV-1 DNA was not detected in any of the 10 fecal 
specimens, however as shown in Figure 5, HIV-1 RNA was detected in 2 out of 5 
patients with detectable viral load. 
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Figure12: Detection of HIV-1 RNA from 2007 frozen feces from HIV-1 infected donors Lane 
1,3,4,6,9( Green): MACS donor without HAART, Lane 2,5,7,8,10( Red): MACS donor with 
HAART. Lane 11: RT control, Lane12: PCR negative control. Lane 6: XX274, viral load 55396, 
Lane 9: XX289, viral load 14690 were both detected in HIV-1 RNA. 
 
4.6: Detection of HIV-1 RNA/DNA and CD4mRNA from 2008 MACS 
volunteer fecal specimens: 
 
4.6.1 Collection of biological specimens from MACS volunteers in 2008: 
Four groups of MACS volunteers were recruited.  Group A: composed of 10 
MACS volunteers who were HIV-1 negative;  Group B: composed of 11 HIV-1 
infected MACS volunteers with detectable viral load in plasma ranging from 428 
to 78,636 and CD4+ T cell count ranging from 149 to 923. All these volunteers 
from this group were without any antiretroviral therapy; Group C: composed of 
13 HIV-1 infected MACS volunteers with non-detectable viral load in plasma and 
CD4+ T cell count ranging from 385 to 922. All the volunteers from this group 
were under antiretroviral therapy; Group D: composed of 5 HIV-1 infected MACS 
volunteers with detectable viral load in plasma ranging from 186 to 33751 and 
CD4+ T cell count ranging from 152 to 540. All the volunteers from this group 
3 7 
1kb 
800bp 
600bp 
1 2 5 4 8 6 9 10 11 12 
Expected size of PCR 
product: 680bp 
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were receiving antiretroviral therapy (Table 3). At the time of feces collection, 
patient’s blood and urine samples were also collected.  
 
Table 3: Clinical information of 2008 Multicenter AIDS Cohort Study (MACS) 
Volunteers 
 ID Sample Date Viral 
Load(copies/ml) 
CD4/mm3 
XX110 8/27/2008 N/A 642 
XX712 8/16/2008 N/A 1317 
XX163 8/19/2008 N/A 899 
XX983 8/19/2008 N/A 1153 
XX271 9/5/2008 N/A 828 
XX003 9/16/2008 N/A 547 
XX744 9/25/2008 N/A 1520 
XX186 9/24/2008 N/A 839 
XX148 9/17/2008 N/A 724 
 
 
 
GroupA=HIV-1  
Negative 
 
N= 10 
XX021 8/19/2008 N/A 845 
XX280 8/26/2008 1003 923 
XX495 8/16/2008 35471 238 
XX326 8/23/2008 20149 392 
XX286 9/17/2008 2974 320 
XX119 8/26/2008 18231 301 
XX200 8/26/2008 58200 149 
XX305 9/4/2008 582 388 
XX053 9/26/2008 78636 406 
XX109 9/25/2008 428 358 
XX013 9/12/2008 20441 457 
  
 
 
 
GroupB=HIV-1 
Positive/No 
antiretroviral 
treatment(HAART) 
 
N = 11 
XX634 9/18/2008 6779 352 
XX484 8/19/2008 <50 440 
XX008 8/20/2008 <50 890 
XX523 9/5/2008 <50 696 
XX245 9/23/2008 <50 566 
XX163 9/10/2008 <50 549 
 
 
 
 
GroupC=HIV-1 
Positive/ HAART/ Non- XX690 9/9/2008 <50 385 
(Table 3 Continued) 
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XX005 8/28/2008 <50 777 
XX144 8/28/2008 <50 583 
XX154 8/20/2008 <50 922 
XX327 9/30/2008 <50 426 
XX350 9/3/2008 <50 466 
XX263 9/17/2008 <50 697 
detectable viral load  
                   
N = 13        
XX265 9/25/2008 <50 478 
XX127 9/3/2008 694 161 
XX229 8/28/2008 186 540 
XX371 9/10/2008 33751 152 
XX099 9/23/2008 842 153 
GroupD=HIV-1 
Positive/HAART/ 
detectable viral load 
N=5 
 
                        
XX274 9/9/2008 16842 279 
 
4.6.2 Detection of HIV-1 DNA in feces from 2008 MACS volunteers fecal 
specimens 
DNA was isolated using NUCLISENS method from 200mg fecal specimen 
followed by nested-PCR using the same primer set described previously. For every 
DNA sample, human beta-globin gene was PCR amplified to ensure the 
comparable amount of human DNA contained in the isolated DNA sample. Beta 
globin gene was detected in 17 out of 39 fecal specimens. Among these 17 beta 
globin positive samples were 1of 10 from Group A, 8 of 11 from Group B, 3 of 13 
from Group C and 5 of 5 from Group D. The representative gel picture of this beta 
globin detection is shown below in Figure 13A. However, HIV-1 DNA was 
detected only in one fecal specimen from a patient with detectable viral load 
(XX326, viral load 20,149, Group B) as shown below in Figure 13B. 
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Figure 13A: Representative figure of Detection of human beta-globin from 2008 MACS donor 
feces sample.Lane1, 2: human beta-globin from MACS donors, 3, 4: human beta-globin not 
detected, Lane 5: PCR control. 
             13B: Representative figure of Detection of HIV-1 DNA from 2008 MACS donor feces 
sample. Lane1: Subject XX495; HIV-1 DNA detected. 
  
4.6.3 Detection of HIV-1 RNA in feces from 2008 MACS volunteers fecal 
specimens: 
RNA was isolated using NUCLISENS method from 200mg of fecal specimen, 
followed by RT nested-PCR. Initially, HIV-1 env specific RT primer, ED12, was 
used to synthesize cDNA from isolated RNA samples followed by nested-PCR 
using the same primer set for HIV-1 DNA amplification. To serve as the human 
RNA input control in each sample, cDNA was synthesized from the RNA sample 
using random hexamer followed by nested PCR amplification with human beta-
37 
 
actin mRNA specific primers. As demonstrated in Figure 14, relatively equal 
amounts of beta actin mRNA were detected from all isolated fecal RNA, whereas 
HIV-1 RNA was detected in 3 out of 16 (19%) patients with detectable viral load 
in blood.  
 
 
Figure 14A: Representative picture of detection of Human beta actin mRNA from 2008 MACS 
donor feces sample. Lane 1-6: MACS donor feces samples, Lane 7: PCR negative control, Lane 
8: RT negative control, Lane 9: RT control 
 
14B: Representative picture of detection of HIV-1 RNA from 2008 MACS donor feces sample. 
Lane 1-7: MACS donor feces samples, Lane 8: PCR negative control, Lane 9: RT negative 
control, Lane 10: RT control  
 
4.6.4: Confirmation of PCR specificity by using primers for another region 
(Gag) of HIV-1 genome: 
To confirm the PCR amplification specificity of HIV env target, another primer 
pair, binding to HIV gag region, was designed and used for RT-nested PCR as 
described previously. Two out of three env positive and two out of two envelope 
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negative fecal RNA samples maintained the identical outcome using Gag specific 
primers ( Figure 15). 
 
 
Figure 15: Confirmation of PCR specificity by using primers from another region (Gag) of HIV-
1 genome. Lane 1-5: MACS donor feces samples, Lane 6: RT control, Lane 7: RT negative 
control, Lane8: PCR positive control, Lane 9: PCR negative control. 
 4.6.5 Detection of Human CD4 mRNA from MACS volunteer fecal 
specimens: 
To monitor CD4 mRNA contained in isolated fecal RNA samples from MACS 
donors, human CD4 mRNA specific RT and nested PCR primers were designed to 
amplify 110 bp PCR products. Human CD4 mRNA was detected in 5 out of 16 
(32%) patients with detectable viral load in blood.Whereas, no CD4 mRNA was 
detected in any HIV-1 uninfected donor’s fecal specimens. The representative 
result of human CD4mRNA detection by nested RT-PCR has been shown below in 
figure 16. 
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Figure 16: Representative picture of detection of human CD4mRNA from 2008 MACS donor 
feces. Lane 1-5: MACS donor feces samples, Lane 7: PCR negative control, Lane 8: RT negative 
control, Lane 9: RT control 
All the results from 2008 MACS donor fecal samples are summarized below in 
Table 4. 
Table 4: Summary of detection of HIV-1RNA/DNA in fecal specimens of 2008 
Multicenter AIDS Cohort Study (MACS) volunteers. 
 Group A 
(HIV 
Negative) 
Group B 
(HIV+/HAART Naive) 
Group C 
(HIV+/HAART/ Non-
detectable viral load) 
Group D 
(HIV+/HAART/ 
detectable viral 
load) 
HIV-1 RNA 0/10 2/11 0/13 1/5 
HIV-1 DNA 0/1 1/8 0/3 0/5 
CD4mRNA 0/10 3/11 0/13 2/5 
 
Numerator = Number of subjects detected with HIV-1 RNA/DNA and  
                       CD4mRNA.         
Denominator = Total number of subjects whose housekeeping genes (beta actin/ 
beta globin) were detected 
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4.7: Detection of HIV-1 p24 antigen from MACS donor feces samples: 
To detect HIV protein from MACS donor feces samples, HIV-1 p24 ELISA was 
performed in all fecal specimens. Two hundred milligram of MACS donor feces 
sample were treated with protease inhibitor cocktail (Roche) and tested for HIV-1 
p24 antigen. No HIV-1 p24 in the fecal extracts from these donors were detected in 
ELISA. HIV-1 p24 was detected in normal donor feces sample spiked with HIV-1 
positive culture supernatant. 
 
4.8: Detection of fecal occult blood from 2008 MACS donor feces samples: 
To detect the possible blood content in the fecal samples, an occult blood test was 
performed in all 2008 MACS fecal specimens as described in Materials and 
Methods section. As shown in Table 4, fecal blood was detected in 7 out of 39 
MACS specimens: 2 from Group A(HIV-1 Negative), 1 from Group B (HIV-1 
infected/ Not under HAART), 3 from Group C (HIV-1 infected/under HAART/ 
non-detectable viral load) and 1 from Group D (HIV-1 infected/under HAART/ 
detectable viral load)( Table 5). Fecal occult blood test was negative for the fecal 
samples which were HIV-1 RNA or DNA positive. One of the five CD4mRNA 
positive fecal specimens was positive for occult blood; the remaining samples were 
negative.  
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Table 5: Summary of detection of Fecal Occult blood in 2008 Multicenter AIDS 
Cohort Study(MACS)volunteers. 
 
Group ID Sample 
Date 
Viral 
Load(copies/ml) 
CD4/mm3 Fecal Occult Blood 
detection(Yes/No) 
XX271 9/5/2008 N/A 828 Yes  
Group A= HIV  negative XX744 9/25/2008 N/A 1520 Yes 
Group B = HIV-1 Positive/ 
Noantiretroviral 
treatment(HAART) 
 
XX053 9/26/2008 78636 406 Yes 
XX245 9/23/2008 <50 566 Yes 
XX690 9/9/2008 <50 385 Yes 
Group C = HIV -1 Positive/ 
HAART/Non-detectable 
viral load  
 
XX265 9/25/2008 <50 478 Yes 
Group D = HIV-1 Positive/ 
HAART/ detectable viral 
load 
 
XX099 9/23/2008 842 153 Yes 
 
 
SPECIFIC AIM #3: Detection of HIV-1 DNA/RNA in urine specimens of 
Multicenter AIDS Cohort Study volunteers and correlation of the outcome with 
results from the blood and fecal specimens. 
 
4.9 Measurement of HIV-1 RNA/DNA from 2008 MACS Volunteers : 
Urine samples, volume ranging from 19ml-80ml, were processed to acquire urine 
concentrated supernatant and pellet as described in the Materials and Methods 
section. DNA and RNA were isolated from the urine pellet and concentrated 
supernatant, respectively. 
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4.9.1: Detection of HIV-1 RNA/DNA from 2008 MACS volunteer urine 
specimen:    
 
Figure 17A: Representative picture of detection of human beta globin from Urine sample. Lane 
1-9: beta globin detected  17B: Representative picture of detection of HIV-1 DNA from Urine 
sample.Lane 1-4: HIV-1 DNA detected, Lane 5: PCR control 
 
HIV env region was amplified from the DNA purified from the MACS donor urine 
pellet in nested-PCR reaction using the same env primer set described above. For 
each DNA sample, human beta-globin gene was PCR amplified to ensure the 
comparable amount of human DNA contained in the isolated DNA sample.Table 6, 
shows that all urine pellet samples were positive for beta-globin amplification. 
HIV-1 DNA was detected in 5 urine pellet samples from HIV infected patients, 3 
of 5 with detectable viral load, and 2 of 6 with undetectable viral load. 
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4.9.2: Detection of HIV-1 RNA from MACS Volunteer urine specimen: 
 
HIV env region was amplified from RNA purified from the urine supernatant by 
RT nested-PCR. Initially, HIV env specific RT primer, ED12, was used to 
synthesize cDNA from isolated RNA samples followed by nested-PCR using the 
same primer set for HIV DNA amplification. As shown in Figure 18, HIV-1 RNA 
was detected in one concentrated urine sample from a patient with detectable viral 
load. 
 
Figure 18: Detection of HIV-1RNA in urine specimens of 2008 Multicenter AIDS Cohort Study 
(MACS) volunteers. 
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Summary of detection of HIV-1RNA/DNA in Urine specimens of 2008 
Multicenter AIDS Cohort Study (MACS) donors are shown below in Table 6. 
 
Table 6: Summary of detection of HIV-1RNA/DNA in Urine specimens of 2008 
Multicenter AIDS Cohort Study (MACS) volunteers. 
 
 Group A= 
HIV  
Negative 
Group B = HIV-1 Positive/ 
Noantiretroviral 
treatment(HAART) 
 
GroupC=HIV-1 
Positive/ HAART/ Non-
detectable viral load  
 
GroupD=HIV-1 
Positive/HAART/ 
detectable viral load 
 
 
HIV-1 
RNA 
0/9 1/10 0/8 0/9 
HIV-1 
DNA 
0/9 2/10 3/9 2/8 
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Now overall summary of detection of HIV-1RNA/DNA/ human CD4mRNA /fecal 
occult blood from 2008 Multicenter AIDS Cohort Study (MACS) volunteers are 
shown below in Table 7. 
 
Table 7: Summary of detection of HIV-1RNA/DNA/ human CD4mRNA /fecal 
occult blood from 2008 Multicenter AIDS Cohort Study (MACS) volunteers.  
Group A: total numbers of subjects detected= 2, Group B: total numbers of 
subjects detected= 8, Group C: total numbers of subjects detected= 5, Group D 
total numbers of subjects detected= 3  
 
 
URINE 
 
FECES 
Group  
 
ID 
 
Viral 
Load(copies
/ml) 
 
 
CD/mm3  
HIV-
1DNA 
 
HIV-1 
RNA 
 
HIV-1 DNA 
 
HIV-1 RNA 
CD4 
mRNA 
Fecal occult 
blood 
XX271 N/A       +  
Group A 
(N=10) 
XX744 N/A       + 
XX053 78636 406      + 
XX280 10003 923     + - 
XX495 35471 238   +   - 
XX326 20149 392    +  - 
XX286 2974 320     + - 
XX119 18231 901  +  + + - 
XX200 85820 149 +     - 
 
 
 
 
Group B 
(N=11) 
XX013 20441 457 +     - 
XX245 <50 566      + 
XX690 <50 385      + 
XX265 <50 478 +     + 
XX523 <50 696 +     - 
 
 
Group C 
(N=13) 
XX327 <50 426 +     - 
XX099 842 153     + + 
XX274 16862 279 +   + + - 
 
Group D 
(N=5) 
XX371 33751 152 +     - 
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5.0 DISCUSSION 
In this study, we have developed sensitive methods for detection of HIV-1 
RNA/DNA and CD4 mRNA in feces. Using these methods, we have measured the 
amount of HIV-1 RNA/DNA and CD4 mRNA in feces samples from HIV-1 
uninfected as well as HIV-1 infected patients with or without antiretroviral 
therapy. We also determined if this detection correlates with the patient’s viral load 
or not. 
 
The components of human feces are very complex, containing DNA/RNA and 
proteins from different species, proteases, various inhibitors[44]. However, fecal 
samples, which can be obtained easily by non-invasive technique, have been used 
in laboratory tests for intestinal pathogens or other diseases, such as: antibody-
antigen type test to look for a specific virus, microscopic examination for intestinal 
parasites, laboratory culture to find bacterial and viral pathogens and PCR/RT-PCR 
to detect viral nucleic acid.  Many viral pathogens have been detected from the 
feces, such as astrovirus, rotavirus, coronavirus, calcivirus, adenovirus and 
hepatitis-C virus [45]. However, no comprehensive studies have been performed so 
far on the fecal samples from HIV-1 infected patients. A few available reports in 
the literature showed that HIV-1 RNA has been detected in feces from HIV-1 
infected children and adults [25] at acute stage of infection with high viral load in 
plasma. Furthermore, no reports have been found so far to evaluate HIV and CD4 
mRNA level in feces from patients at chronic stages of disease with or without 
Highly Active Anti retroviral Therapy (HAART).  
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Since the components of human feces are very complex and so far no sensitive 
methods for detection of viral and human RNA/DNA in human feces have been 
established, we have developed the sensitive methods for isolation and detection of 
HIV-1 DNA/RNA and human CD4 mRNA in feces. Our data showed that HIV-1 
DNA was detected from normal donor feces spiked with 8E5 cells with the 
detection limit of 2.5 copies of HIV DNA /reaction. HIV-1 RNA was detected 
from normal feces spiked with HIV positive plasma with detection limit of 40 
copies of HIV RNA/reaction. There is no influence of complex components 
contained in the feces on the isolation and PCR amplification process since HIV 
RNA from the same  HIV-1 positive plasma (without feces) showed a similar level 
of detection .  
 
GALT contains an abundant amount of CD4+ T cells to maintain the mucosal 
immunity. HIV-1 infection causes a massive CD4+ T cell depletion in GALT and 
compromised mucosal immunity[16]. Ideally to monitor HIV-1 related GALT 
pathogenesis, a GI biopsy should be performed regularly to evaluate the dynamic 
changes of CD4 T cells in GALT, however such studies are very difficult to 
implement. We hypothesize that during the massive CD4+ T cell depletion, CD4+ 
T cells shed into intestinal lumen and the amount of CD4+ T cells in the feces 
would associate with the pathogenic changes in GALT. To date no comprehensive 
studies have been performed to monitor the dynamic changes of CD4+ T cell 
levels in feces. In the harsh environment of GI tract, it is very difficult to detect 
and quantitate the intact CD4+ T cells and CD4 proteins in fecal specimens. 
Therefore, we have developed PCR methods to detect CD4 mRNA from feces.  As 
expected, CD4 mRNA was not detected from normal donor feces, but detected 
from normal feces spiked with 50 HIV-1 infected CD4+ 8E5 cells.  
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In order to monitor HIV-1 p24 protein in stool samples from HIV-1 infected 
donors, we have standardized the detection method using normal donor feces 
spiked in vitro with serial dilutions of HIV-1 virus treated with protease inhibitors 
and then detected HIV-1 p24 using a commercially available ELISA kit. ELISA 
data (shown in figure 11), revealed that the detection limit is 15pg/ml, which was 
similar to detection limit observed in HIV-1 virus alone without feces. These data 
showed that the normal fecal constituents are not interfering with the HIV-1 p24 
detection in our currently used method, which have been used in subsequent study 
for HIV-1 p24 detection in MACS donor feces samples.  
 
To evaluate the significance of using fecal specimens to monitor HIV-1 associated 
GALT pathogenesis, we have collected the feces samples from HIV-1 negative and 
HIV-1 infected donors of the Multicenter AIDS Cohort Study (MACS) with or 
without HAART treatment. Among samples collected and frozen for one year,we 
have detected HIV-1 RNA in 2 feces out of 6 with detectable viral load and 
without any anti- retroviral therapy. HIV-1 DNA was not detected from any of the 
fecal specimens. One reason for this lower detection limit could be that the 1 year 
frozen condition reduced the detectable HIV-1 DNA.  
 
DNA/RNA was isolated from 39 freshly frozen fecal samples collected in 2008 
and the amount of human DNA/RNA contained in each sample was quantified. 
Subsequently, HIV-1 DNA/RNA and CD4 mRNA in the samples were tested. Our 
results showed that HIV-1 DNA was detected in 1 subject from Group B (HIV-1 
infected but not on HAART) with detectable viral load of 35,471copies/ml in 
plasma. HIV-1 RNA was detected in two subjects from Group B (HIV-1 infected 
but not on HAART) and in one subject from Group C (HIV-1 infected on 
HAART). The HIV-1 detection rate is lower in feces samples from patients with 
49 
 
detectable plasma viral loads and is lower compared to the 67% detection level 
reported in the paper by Boom et al. However, in the Boom et al. study, all feces 
samples were collected from patients in acute stage of infection, whereas in our 
current study, all feces samples were collected from patients in the chronic stage of 
infection. Also in Boom et al. paper those subjects tested were not receiving 
antiretroviral treatment but all the subjects (in Group C and Group D) were under 
HAART therapy. However the subjects from Group B were not under any HAART 
treatment. So far no comprehensive study has been performed for monitoring the 
HIV-1 status in feces from patients in chronic stage of infection. It is likely that 
levels of HIV shedding from GALT to intestinal lumen is higher in the acute phase 
of infection compared to the later phase of infection because of the rapid 
replication of HIV-1 and destruction of lymphoid tissues that occurs in GALT 
during early phase of infection.  
 
All feces samples were screened for CD4 mRNA, a surrogate marker for CD4+ T 
cells. No CD4 mRNA was detected in any feces samples from the HIV-1 negative 
donors, but CD4 mRNA were detected from 4 out of 5 feces samples from the 
subject with detectable viral load, three from group B (HIV-1 infected but not 
under any HAART) and two from group D (HIV-1 infected on HAART but with 
detectable viral load) .These results suggest that CD4+ T cell shedding from GALT 
to intestinal lumen can be associated with high virus shedding in feces.  
 
Due to the complexity of fecal DNA/RNA contents, it is necessary to validate the 
PCR specificity in the PCR amplification reaction. For this purpose, we designed 
another primer pair hybridizing to the gag region of HIV-1 genome and tested 
them in two HIV negative and three HIV-1 positive feces samples determined 
previously by PCR reaction with env primers. In these selected five samples, the 
50 
 
identical results were observed in four samples with the gag primers. This result 
strongly indicated that the env primers were specifically amplifying HIV-1 env 
regions. However, one HIV positive feces sample determined with env primer 
turned out negative with gag primers. This might be due to the extremely low copy 
number of HIV genomes contained in the sample, which could lead to limited PCR 
positive detection in the PCR amplifications.   
 
Measurement of HIV proteins is another commonly used method for quantitation 
of HIV concentration in a biological specimen. To measure HIV-1 proteins 
contained in feces samples from MACS patients, the HIV-1 gag protein p24, was 
measured by ELISA in the supernatant derived from feces treated with protease 
inhibitors. However, HIV-1 p24 was not detected in any of the feces samples from 
MACS donors including some feces samples with positive HIV-1 RNA result 
(showed in Figure 5). Lack of detection of HIV-1 protein in feces could be due to: 
1) low level of p24 protein present in the sample, which was below the p24 ELISA 
detection limit; 2) HIV-1 p24 proteins might be degraded by proteases in the 
intestinal lumen before voiding out of the GI tract. 3) Sensitivity of detection of 
p24 is much lower than RNA detection as 1pg of HIV-1 p24 is equivalent to 
10,000 copies of RNA. Further experiments are needed to explore these 
possibilities. 
 
Fecal occult blood is a term for blood present in the feces that is not visibly 
apparent. Detection of blood in feces has long been regarded as an indicator of 
patient's state of health[46].  
 
HIV-1 RNA/DNA and CD4 mRNA detected in the fecal specimens of HIV-1 
infected patients could be the result either from internal bleeding in the 
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gastrointestinal tract or from shedding of HIV-1 infected cell and free virus from 
GALT.  To dissect these two possibilities, fecal blood test was performed in all 
2008 samples. As listed in Table 4, a total of 7 fecal samples were positive in the 
test: 2 from Group A, 1 from Group B, 3 from Group C and 1 from Group D. No 
fecal samples positive for HIV-1 RNA/DNA were positive in the occult blood test. 
This result strongly suggests that the HIV-1 RNA/DNA detected in the fecal 
samples were from the shedding of HIV-1 infected cells or virus from GALT into 
intestinal lumen.  
 
To accurately assess the occult blood in fecal sample, certain diet restriction should 
be imposed in a few days before collecting fecal samples. Unfortunately, in this 
study, patients were not informed about the diet restriction before sample 
collection and unrestricted food intake might lead to false positive result in the 
occult blood test. One specimen from Group D (XX099) was positive in occult 
blood test and also positive for CD4 mRNA. Therefore, the CD4 mRNA detected 
in the fecal sample of patient XX099 could be due to the blood contained in the 
feces or CD4+ T cells shed from GALT due to HIV-1 associated pathogenesis. 
Further study is needed to dissect the two possibilities. 
 
Detection of HIV-1 DNA/RNA in HIV-1 infected donor urine was also examined 
as urine could serve as an important vehicle for HIV-1 transmission. A wide range 
of renal diseases have been described in HIV-1 infected patients [47]. Li et al. in 
1992 reported the presence of HIV-1 genomic sequence and gene products from 
fresh urine pellets from HIV-1 seropositive individuals. By using the PCR based 
method HIV-1 DNA proviral sequences were detected in 53 of 80 (66.25%) fresh 
urine pellets from HIV-1-seropositive individuals [27] . But so far no cross 
sectional studies have been shown to detect HIV-1 RNA/DNA from infected 
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donors urine samples in the presence or absence of anti-retroviral therapy. Our data 
showed that it is possible to detect HIV-1 DNA and RNA from an infected donors 
urine pellet and concentrated supernatant respectively regardless of the 
corresponding plasma viral load. A nested RT-PCR and nested DNA PCR were 
chosen for the detection of HIV-1RNA/DNA and CD4mRNA because it is more 
rapid and sensitive for detection. 
 
HIV-1 DNA was not detected in any of urine samples from the HIV negative 
donors, but were detected from 2 out of 10 urine pellets from group B (HIV-1 
infected but not on  HAART) and both of them with high viral load, 3 out of 13 
urine pellets from Group C( HIV-1 infected on  HAART/ non-detectable plasma 
viral load) and 2 out of 5 urine pellets  from group D (HIV-1 infected on HAART 
but with detectable viral load. Thus our data from Table 6 demonstrates that HIV-1 
DNA from urine pellet was detected in patients across a range of plasma viral load. 
This result suggested that HIV-1 DNA detected in urine not always accompanied 
with the shedding of virus in high quantity.  We have detected only one HIV-1 
RNA from subject XX119 from group B (HIV-1 infected but not on HAART). 
 
HIV can be present in a variety of body fluids and secretions like blood, semen, 
vaginal fluids and breast milk, but the presence of HIV-1 in urine in chronic 
infected subjects with or without antiretroviral therapy (HAART) has not been 
addressed yet. On the basis of this inquisition, the question of whether urine is 
potentially an infectious body fluid in HIV-1 infected individual is raised. So far 
attempts of isolating the infectious HIV-1 from urine of HIV-1 seropositive donors   
were largely unsuccessful[48]. Detection of HIV-1 DNA/ RNA from urine of the 
HIV infected individual can be extremely important as this might lead to future 
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work to evaluate whether urine could potentially serve as a vehicle for HIV-1 
transmission. 
 
So far, fecal and urine specimens have not been studied extensively, most likely 
because of the challenges with recovery and inhibition of amplification of viral 
DNA and RNA. Our cross sectional study data based on a simple PCR based 
detection method showed that it is possible to isolate and detect HIV-1 RNA/DNA 
and CD4 mRNA from feces and urine samples. This study indicates that feces and 
urine may therefore be two suitable specimens for diagnosis of HIV-1 infection 
without the need for invasive sampling techniques. In addition the detection of 
CD4mRNA from feces samples could lead to the evaluation of the immune profile 
of Gut Associated Lymphoid Tissue (GALT) of HIV-1 infected individual. 
Knowledge of this detection is of importance in public health for the possible 
future development of therapeutic intervention against HIV-1. Future longitudinal 
studies will reveal whether there is a correlation between onset of gastrointestinal 
symptoms and detection of HIV-1 RNA/DNA and CD4mRNA in feces and urine 
samples of the HIV-1 infected individual. 
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6.0 FUTURE DIRECTIONS 
 
Future studies using this simple non-invasive technique will further explore 
whether it is possible to detect various human gut cytokine mRNA from HIV-1 
infected donor feces. Cytokines are small secreted proteins which mediate and 
regulate immunity, inflammation, and hematopoiesis. They must be produced de 
novo in response to an immune stimulus. Secretion of various gut cytokines in 
fecal specimens in response to HIV-1 infection may reveal the immune activation 
status of the infected individual for future therapeutics development[49]. 
Chemokines like RANTES, MCP-1, MIP-1a, and MIP-1b could be evaluated if 
they could be detected in feces samples.  
 
Future longitudinal study is essential to evaluate the detection of HIV-1 
RNA/DNA and CD4 mRNA in feces and urine samples of the Multicenter AIDS 
Cohort Study Donors. Ideally feces and urine samples need to be tested on 
different time points like 0 month, 3 month, 6 month, 1 year and 2 years in the 
same cohort from MACS donors. This further longitudinal study is necessary to 
correlate the detection of HIV-1 RNA/DNA and CD4mRNA with the disease 
progression and prognosis. 
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7.0 PUBLIC HEALTH IMPLICATION 
 
The study of disease progression and prognosis in AIDS patients with respect to 
immunopathological changes in GALT is challenging because of the limited 
availability of gut tissue from infected donors. Depletion of CD4+ T cells during 
the course of HIV-1 infection is a hallmark of AIDS pathogenesis, but so far the 
specific mechanisms are not well established. Therefore a detection and diagnosis 
approach based on simple noninvasive technique is essential in this aspect.  
The biggest advantage of detecting HIV-1 from urine and fecal samples is that the 
patient does not need to have blood drawn with a needle. This makes it easier and 
less painful to obtain a sample, particularly with very young children. In addition, 
this method of collection is safer for the health-care worker because there is very 
little risk that the worker will be exposed to the virus, something that can occur if 
he or she is accidentally stuck with the same needle used to draw the patient's 
blood. A urine and feces test could become a significant weapon in the battle to 
slow the AIDS epidemic because it makes testing safer, easier and more accessible 
compared with the standard blood test. Thus our cross sectional  study has major 
implications for public health, since through this simple non-invasive method of 
obtaining  feces and urine samples we can assess HIV-1 profile and immune status 
in the gastrointestinal tract of an HIV-1 infected patient.  
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